Education
About Us
Working with TipRanks
Follow Us
Voyager Therapeutics Inc. (VYGR)
:VYGR
VYGR Stock Chart & Stats
$4.81
-$0.14(-2.36%)
At close: 4:00 PM EST
$4.81
-$0.14(-2.36%)
Day’s Range― - ―
52-Week Range$2.65 - $7.44
Previous CloseN/A
Volume91.62K
Average Volume (3M)780.69K
Market Cap
$257.93M
Enterprise Value$7.06M
Total Cash (Recent Filing)$215.59M
Total Debt (Recent Filing)$40.20M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Nov 18, 2025EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding55,468,807
10 Day Avg. Volume615,896
30 Day Avg. Volume780,688
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.03
Enterprise Value/Revenue0.17
Enterprise Value/Gross Profit0.17
Enterprise Value/Ebitda-0.06
Forecast
1Y Price Target
$16.14Price Target Upside235.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
FDA GuidanceVoyager Therapeutics is well positioned to benefit from the FDA’s draft guidances, which support innovation and platform leverage across genetic medicines.
NeuroShuttle PlatformVoyager's ALPL NeuroShuttle platform is considered platform-enhancing and partner-catalyzing, reinforcing the Buy rating and $30 price target.
Platform TechnologyVoyager’s TRACER capsid platform aligns with FDA’s Platform Technology framework, potentially accelerating portfolio development.
Bears Say
Development RisksThere are several risks including clinical development risk, competitor risk, and capital market and dilution risk which could impact the company's future performance.
Voyager Therapeutics News
VYGR FAQ
What was Voyager Therapeutics Inc.’s price range in the past 12 months?
Voyager Therapeutics Inc. lowest stock price was $2.65 and its highest was $7.44 in the past 12 months.
What is Voyager Therapeutics Inc.’s market cap?
Voyager Therapeutics Inc.’s market cap is $257.93M.
When is Voyager Therapeutics Inc.’s upcoming earnings report date?
Voyager Therapeutics Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 20 days.
How were Voyager Therapeutics Inc.’s earnings last quarter?
Voyager Therapeutics Inc. released its earnings results on Aug 06, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.526 by -$0.044.
Is Voyager Therapeutics Inc. overvalued?
According to Wall Street analysts Voyager Therapeutics Inc.’s price is currently Undervalued.
Does Voyager Therapeutics Inc. pay dividends?
Voyager Therapeutics Inc. does not currently pay dividends.
What is Voyager Therapeutics Inc.’s EPS estimate?
Voyager Therapeutics Inc.’s EPS estimate is -0.52.
How many shares outstanding does Voyager Therapeutics Inc. have?
Voyager Therapeutics Inc. has 55,468,807 shares outstanding.
What happened to Voyager Therapeutics Inc.’s price movement after its last earnings report?
Voyager Therapeutics Inc. reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.526. Following the earnings report the stock price went down -5.294%.
Which hedge fund is a major shareholder of Voyager Therapeutics Inc.?
Currently, no hedge funds are holding shares in VYGR
Voyager Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.14 (235.55% Upside)
$16.14 (235.55% Upside)
Blogger Sentiment
Bullish
VYGR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $107.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 11.7%
Last 30 Days ▲ 11.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.74%
12-Months-Change
Fundamentals
Return on Equity
-37.26%
Trailing 12-Months
Asset Growth
-26.16%
Trailing 12-Months
Company Description
Voyager Therapeutics Inc.
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
VYGR Stock 12 Month Forecast
Average Price Target
$16.14
▲(235.55% Upside)
Technical Analysis
Galectin Therapeutics
―
Cartesian Therapeutics
―
Silence Therapeutics
―
Tenaya Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
2.24% Insiders
12.04% Mutual Funds
0.54% Other Institutional Investors
75.61% Public Companies and Individual Investors